USFDA Guidance: Dose Banding - Labeling for Dosing Based on Weight or Body Surface Area
USFDA MD Guidance: AST System Devices, Technical Considerations & Electronic Submission Template
USFDA MD Guidance: Cybersecurity-Quality System Considerations & Content of Premarket Submissions
USFDA Guidance: Formal Meetings Between the FDA and Sponsors or Applicants -PDUFA Products
USFDA Guidance: Conduct of Clinical Trials of Medical Products During Major Disruptions
USFDA Guidance: Regulatory Considerations for Prescription Drug Use-Related Software
USFDA Guidance: Labeling for Biosimilar & Interchangeable Biosimilar Products
USFDA M.D Guidance: Med Dev Associated with Weight Loss & Voluntary Improvement Program
USFDA Guidance: IRB Review of Individual Patient Expanded Access Submissions & Peptide Drug Products
![USFDA Guidance: Premarket Notification [510(k)] Submissions](https://static.wixstatic.com/media/nsplsh_453363554d4e4263424363~mv2.jpg/v1/fill/w_1596,h_1200,fp_0.50_0.50,q_90,enc_auto/nsplsh_453363554d4e4263424363~mv2.jpg)
USFDA Guidance: Premarket Notification [510(k)] Submissions
USFDA Guidance: Post-Warning Letter Meetings & Interoperable Exchange of Information
USFDA Guidance: Informed Consent Guidance for IRBs, Clinical Investigators, & Sponsors
USFDA Guidance: Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products
USFDA Guidance: QTc Information in Prescription Drug & Biological Product Labeling
USFDA Guidance: Recommended Acceptable Intake Limits for Nitrosamine DS-Related Impurities
USFDA Guidance: Waivers, Exceptions, & Exemptions from Section 582 of FD&C Act
USFDA Guidance: Assessing User Fees -BsUFA III: Biosimilar User Fee Amendments of 2022
USFDA Med Dev Guidance: On Opioid Use Disorder & Hydrogen Peroxide-Based Contact Lens Care Products
USFDA Guidance: ICH M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities
USFDA Guidance: Qualification of Medical Device Development Tools